Trial · NCT00528645
Adverse events54
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 54
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Treatment (Saracatinib) | 20 | 23 | 39 |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Saracatinib) | 6 | 23 | 26 |
| other | Lower gastrointestinal hemorrhage | Gastrointestinal disorders | Treatment (Saracatinib) | 1 | 23 | 1 |
| other | Nausea | Gastrointestinal disorders | Treatment (Saracatinib) | 9 | 23 | 12 |
| other | Vomiting | Gastrointestinal disorders | Treatment (Saracatinib) | 7 | 23 | 9 |
| other | Fatigue | General disorders | Treatment (Saracatinib) | 16 | 23 | 45 |
| other | Fever | General disorders | Treatment (Saracatinib) | 1 | 23 | 1 |
| other | Hepatic failure | Hepatobiliary disorders | Treatment (Saracatinib) | 1 | 23 | 1 |
| other | Bladder infection | Infections and infestations | Treatment (Saracatinib) | 1 | 23 | 1 |
| other | Skin infection | Infections and infestations | Treatment (Saracatinib) | 1 | 23 | 1 |
| other | Alanine aminotransferase increased | Investigations | Treatment (Saracatinib) | 1 | 23 | 1 |
| other | Alkaline phosphatase increased | Investigations | Treatment (Saracatinib) | 1 | 23 | 1 |
| other | Aspartate aminotransferase increased | Investigations | Treatment (Saracatinib) | 2 | 23 | 2 |
| other | Bilirubin increased | Investigations | Treatment (Saracatinib) | 1 | 23 | 1 |
| other | Creatinine increased | Investigations | Treatment (Saracatinib) | 8 | 23 | 19 |
| other | Laboratory test abnormal | Investigations | Treatment (Saracatinib) | 1 | 23 | 1 |
| other | Leukocyte count decreased | Investigations | Treatment (Saracatinib) | 5 | 23 | 5 |
| other | Neutrophil count decreased | Investigations | Treatment (Saracatinib) | 1 | 23 | 2 |
| other | Platelet count decreased | Investigations | Treatment (Saracatinib) | 7 | 23 | 8 |
| other | Weight loss | Investigations | Treatment (Saracatinib) | 1 | 23 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00528645/events